7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
NEW YORK, Aug. 26, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) securities June 24, 2015 through July 25, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/tokai-pharmaceuticals-inc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Defendants issued false and/or misleading statements to investors and/or failed to disclose that: (1) there were noteworthy structural problems with ARMOR3-SV, the trial design for Tokai's pivotal Phase 3 Galeterone study, (2) accordingly, ARMOR3-SV would probably not meet its primary endpoint; (3) therefore, the likelihood of Galeterone's commercialization was not as probable as Tokai had told investors; and (4) consequently, Tokai's financial statements were false and misleading and/or lacked a reasonable basis.
Additionally, on July 26, 2016, Tokai announced it would end a late-stage trial of Galeterone, saying it believed the stage 3 study would not meet its primary endpoint. Following this news, Tokai shares fell from $5.20 on July 25, 2016, to a close of $1.10 on July 26, 2016.
If you suffered a loss in Tokai you have until September 30, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/tokai-pharmaceuticals-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
